Genetic, hormonal and metabolic aspects of PCOS: an update.

De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. · 2016

Read Genetic, hormonal and metabolic aspects of PCOS: an update. by De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4947298.txt.

Introduction

V. De Leo and five co-authors update the genetics, hormones, and metabolism of polycystic ovary syndrome. Their review appeared in Reproductive Biology and Endocrinology in 2016. The syndrome affects 5 to 10 percent of women of reproductive age. It shows as irregular or absent ovulation, excess male type hormones, and polycystic ovaries on ultrasound. Insulin resistance is also common. The review treats the condition as a whole body disorder, not only a fertility problem.

Diagnosis follows the 2003 Rotterdam rules, which require two of the three main features. The authors weigh gene, hormone, and environmental inputs, since no single cause explains the syndrome. Patients face higher risk of metabolic and heart disease than the general population. Care tools include hormonal contraceptives, antiandrogen drugs, metformin, and inositols. The authors argue early diagnosis matters most, because prompt care can prevent or delay the long term harms.

Catalog record

CREATORDe Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE82 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4947298

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Genetic, hormonal and metabolic aspects of PCOS: an update By V. De Leo, M. C. Musacchio, V. Cappelli, M. G. Massaro, G. Morgante, F. Petraglia Published in: Reproductive Biology and Endocrinology : RB&E DOI: 10.1186/s12958-016-0173-x ABSTRACT Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting 5–10 % of women of reproductive age. It generally manifests with oligo/anovulatory cycles, hirsutism and polycystic ovaries, together with a considerable prevalence of insulin resistance. Although the aetiology of the syndrome is not completely understood yet, PCOS is considered a multifactorial disorder with various genetic, endocrine and environmental abnormalities. Moreover, PCOS patients have a higher risk of metabolic and cardiovascular diseases and their related morbidity, if compared to the general population. BACKGROUND Definition and diagnostic criteria Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women and major cause of anovulatory infertility. PCOS patients can present a wide range of signs and symptoms, which make difficult the precise grading of the condition. Diagnosis of PCOS is currently based on the criteria of the ESRHE/ASRM Rotterdam consensus meeting in 2003 [1], which broadened the previous NIH classification of 1990 [2]. It based on at least two of the following features: oligo-anovulation, hyperandrogenism and polycystic ovaries by ultrasound [1]. In 2006, the Androgen Excess Society (AES) set up a committee of experts to review all the data published on PCOS for the purpose of simplifying diagnosis [3]. The AES criteria require clinical and/or biochemical hyperandrogenism simultaneously with oligo/anovulation and ultrasonographic evidence of polycystic ovaries. Although the aetiology of PCOS is not completely understood yet, PCOS is considered a multifactorial disorder with various genetic, metabolic, endocrine and environmental abnormalities [4] There is increasing evidence suggesting that PCOS affects the whole life of a woman, can begin in utero in genetically predisposed subjects, it manifests clinically at puberty, continues during the reproductive years. It can also expose patients to increased risk of cardiovascular disease, hypertension, diabetes and other metabolic complications, especially after menopause [4]. During the fertile period it may cause anovulatory infertility and could be associated with increased prevalence of gestational complications, such as miscarriage, gestational diabetes and preeclampsia [5]. Early diagnosis is therefore crucial by enabling close follow-up and in an attempt to reduce the risk of such complications. It is now widely recognised that insulin resistance, manifesting above all in obese or overweight women, but often also in lean PCOS women, is one of the key to this complex disorder. It determines hyperandrogenism by acting synergically with luteinising hormone (LH) on ovarian steroidogenic enzymes and on sex hormone-binding globulin (SHBG) production by the liver [5]. Diagnostic workup includes hormonal evaluation of androgen levels, clinical evaluation of hirsutism trough Ferriman-Gallwey score and ultrasonographic examination of the number of antral follicles and ovarian volume. Insuline resistance should be evaluated by HOMA INDEX (product of fasting plasma insulin [mU/L] and glucose [mmol/L] concentrations divided by 22.5). Future diagnostic approaches could be ultrasonographic 3D evaluation of follicles and is under discussion the role of anti-mullerian hormone (AMH) [6, 7]. Etio-pathogenesis and pathophysiology: role of genetic, environmental and endocrine factors Genetic and endocrine factors, together with environmental influences. In the research of etiopathogenesis of the syndrome and in the subsequent pathophysiological expression play a role genetic and endocrine as well as environmental factors. The most interesting hypothesis was proposed by Franks et al. [4], who defined PCOS as a genetically determined ovarian pathology characterised by over-production of androgens and manifesting heterogeneously according to the interaction of this genetic “predisposition” with other genetic and environmental factors. This hypothesis is persistent by the finding of polycystic ovaries in pre-pubertal girls [4, 8]. Studies in rhesus monkeys have demonstrated that exposure of foetuses to high levels of androgens during intrauterine life determines the onset of clinical manifestations of PCOS during adolescence. Studies in sheep have shown that an excessive androgen exposure during foetal life influences early ovarian follicular activity and it may explain the typical altered folliculogenesis shown in PCOS [4, 8]. The aforementioned observations may suggest that exposure of the foetal hypothalamus-pituitary-ovarian axis to androgen excess may trigger a series of events that could determine PCOS onset of at puberty. The source of intra-uterine androgens excess is unlikely to be maternal, since the foetus is protected by placental aromatase activity and by high maternal SHBG concentrations. The expression of aromatase in the placenta of PCOS women may be diminished [9] and this could potentially be unable to prevent foetal testosterone (T) excess in PCOS pregnancies [10]. It has been seen that the prevalence of decreased aromatase required to carry out T excess in female fetuses was reported to be extremely rare [11]. On the other hand, recent studies on hypertensive preeclamptic pregnancies have demonstrated a significant reduction in placental ability to synthesize oestrogens, indicating a gestational impairment of T aromatization that is more common than was previously considered [12, 13]. The source of androgens excess is more likely to be the foetal ovary, which is normally quiescent, but it could produce an excess of androgens in response to maternal hCG in subjects genetically predisposed to PCOS. In newborn daughters of PCOS women, elevated T levels have been observed in the umbilical venous blood [14, 15]. This finding was not confirmed in other studies that demonstrated instead a reduced umbilical cord blood androstenedione levels [9, 16]. Hichey et al., showed no increase in T levels in umbilical cord blood of adolescent girls diagnosed with PCOS [17]. Taken the ovary as a key foetal site for gestational T excess, during critical mid-gestational age for target organ differentiation [9], studies at the time of birth, are likely to be too late to detect any remaining hormonal differences [18, 19]. The mid-gestational T excess in human female foetuses can be accompanied by gestational hyperglycaemia and foetal hyperinsulinemia. Interestingly, elevated mid-gestation maternal T levels predict high AMH levels in adolescent daughters [20]. Since elevated AMH represents a characteristic of adolescents and women with PCOS [21] and daughters of PCOS women [22, 23], such associations might suggest a cross-generational relationship between the degree of maternal hyperandrogenism and the development of PCOS in their daughters. Complete manifestation of the syndrome occurs at adolescence, when the hypothalamus-pituitary-ovarian access is activated. At this time, metabolic changes leading to modifications in the distribution of body fat also occur. In particular, at puberty there is a physiological increase in insulin levels, determining on one hand a reduction in SHBG levels with amplification of the effects of circulating androgens, and on the other hand, direct stimulation of ovarian steroidogenesis [24]. In women with PCOS, the physiologic hyperinsulinemia of adolescence may be a triggering factor for the development of hyperandrogenism and anovulation. Girls predisposed to insulin-resistance and overweight are even more at risk of developing early adrenarche and subsequent PCOS at adolescence [24] (Fig. 1).Fig. 1Theory of prenatal origin of PCOS and its development at puberty Daughters of women with PCOS evaluated during early childhood (age 4–8 years) and early puberty (age 9–13 years) have exaggerated adrenarche compared with daughters of non-PCOS women of similar pubertal stage and body mass index (BMI) [25]. This is consistent with a role of obesity-related insulin- resistance in causing hyperandrogenemia in these girls through an effect of

Read the complete text